China SXT Pharmaceuticals, Inc. SXTC PHARMA
Company Overview
China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers Advanced TCMP, including Directly-Oral-TCMP, and After-Soaking-Oral TCMP; Fine TCMP and Regular TCMP products; and raw medicinal material, such as SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. The company serves pharmaceutical companies, chain pharmacies, and hospitals, as well as pharmaceutical distributors. China SXT Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Taizhou, China.
Recent Developments
- Mar 2026 Revenue of $1.14M (-34.6% YoY); net profit $-6.21M.
- Trailing 12 Months Year-on-year growth — revenue -43.9%.
- 5-Year Trend Long-term compounding — revenue CAGR -16.7%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -16.74% |
| 1 Year: | -43.90% |
Stock Price Performance
| 1 Year: | -99.07% |
| 6 Months: | -98.69% |
| 3 Months: | -98.19% |
| 1 Month: | -39.13% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)23.33 · Oversold
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Revenue declined at -16.7% CAGR over 5 years.
- Trading 100.0% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
- RSI at 23 suggests oversold conditions.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | SXTC China SXT Pharmaceuticals, Inc. PHARMA | 2.24 | -0.00 | $2.96M | 0.00% | -23.43% | -27.49% | -16.74% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Profit & Loss (Annual)
Figures in USD.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | - | 1.97M | 1.93M | 1.74M | 1.14M |
| Cost of Revenue | - | 1.55M | 1.37M | 1.37M | 889.35K |
| Gross Profit | - | 426.27K | 553.97K | 367.43K | 248.70K |
| Operating Expenses | - | 6.03M | 3.07M | 3.05M | 7.37M |
| Operating Income | - | -5.61M | -2.52M | -2.68M | -7.12M |
| EBITDA | - | -5.21M | -2.28M | -2.50M | -6.00M |
| Interest Expense | - | 476.78K | 544.28K | 648.22K | 62.97K |
| Pretax Income | - | -5.93M | -3.10M | -3.30M | -6.21M |
| Tax Provision | - | 0 | 0 | 0 | 0 |
| Net Income | - | -5.93M | -3.10M | -3.30M | -6.21M |
| Diluted EPS | -85,613.36 | -15,576.83 | -1,676.69 | -348.17 | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Total Assets | - | 29.55M | 23.13M | 21.66M | 34.75M |
| Current Assets | - | 19.52M | 14.23M | 21.30M | 34.51M |
| Cash & Equivalents | - | 17.37M | 12.07M | 18.10M | 28.18M |
| Inventory | - | 531.25K | 794.86K | 828.05K | 777.06K |
| Receivables | - | 1.34M | 1.31M | 1.30M | 931.57K |
| Total Liabilities | - | 14.86M | 9.20M | 6.22M | 5.05M |
| Current Liabilities | - | 14.50M | 8.90M | 6.01M | 4.35M |
| Long Term Debt | - | 117.86K | 117.13K | 96.26K | 644.39K |
| Total Debt | - | 3.76M | 2.65M | 983.88K | 1.12M |
| Total Equity | - | 14.69M | 13.93M | 15.44M | 29.71M |
| Shares Outstanding | - | 4 | 23 | 1.15K | 11.98K |
Cash Flows (Annual)
Figures in USD.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -80.76K | -1.93M | -2.35M | -4.02M |
| Investing Cash Flow | - | -12.30K | 26.42K | 63.52K | -1.25M |
| Financing Cash Flow | - | 2.94M | -2.62M | 8.40M | 14.43M |
| Capital Expenditure | - | -70.68K | -7.06K | -2.02K | -1.25M |
| Free Cash Flow | - | -151.44K | -1.94M | -2.35M | -5.27M |
| Net Change in Cash | - | 2.85M | -4.53M | 6.12M | 9.17M |
Ratios (Annual)
Figures in %.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Gross Margin % | - | 21.6% | 28.7% | 21.1% | 21.9% |
| Operating Margin % | - | -284.4% | -130.4% | -154.0% | -625.9% |
| Net Margin % | - | -301.0% | -160.7% | -189.8% | -545.2% |
| ROE % | - | -40.4% | -22.2% | -21.4% | -20.9% |
| ROCE % | - | -37.2% | -17.7% | -17.1% | -23.4% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Sabby Management, LLC | 8.16% | 78.17K | $187.61K |
| 2 | UBS Group AG | - | 1 | $2 |
| 3 | Royal Bank of Canada | - | 13 | $31 |
| 4 | Caitong International Asset Management Co., Ltd | - | 2 | $4 |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for SXTC
Why China SXT Pharmaceuticals (SXTC) Stock Is Down Today - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMimAFBVV95cUxOT2ZudE1OUERQTmtKbzNSV0JCQnZLMGpWS0N3RlBjbjZoM19hMUJMS3VYSTRGN2pHdTU3dXZhNXVZNkhfTlpUeEtuWm9NNFV5bE9DM3FpbEQyYzNUbHRROWg4aTlKaGR1Y3I2NElObzE4M0t3VUFwamt5SUE0ZFdhak5vbUJxTklCQ0lvcU…
China SXT Pharmaceuticals, Inc. Announces Share Consolidation - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMipwFBVV95cUxOMDFZa2xWYzNUNkN3NTJuaXFJaVk4R19EdEN0Tm8zT1hsbGFtd3VLUGNReENRNTEtNDRlcGZpVEJvZGtXQU5XcDdvVlhNYkJ2VWw4T3VFT2o1S3NPb3RTRGYwY2hucnZIVEdwZ2ZXRUU2a1h4dXU5UnZnSXZtVlB5RkRhczBqMTFza3JzYS…
China SXT Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:SXTC - tradingview.com
<a href="https://news.google.com/rss/articles/CBMid0FVX3lxTE41WTR0TFdwVDk1VUNtSVNCcE03NEpsNE5zR20tX2Y2MWR4ODFDdGZWOTNwRmlSa2hYYWtKUEF3bmp1NlZ5SC1VcnU5QVNWT1hEX1dIYTdLVWNQNlNPZEg2c3E1UXU0VnhHVWYyN29xc1liQ0lSd3Q0?oc=5" target="_blank">China S…
China SXT Deal Pairs 4.5M Shares With One-Year Warrants - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxPckxuTTdqdWJCSlN2OHlDWTZXbF94dW04b0JvV0YydXFKYVJXR1Y1UGNIOE5FdkdTNGs4RVlCSWg4UElRRFVyYzh2S2pRYk1RWXFCck1pYmlMb29YYnA2Q1M4amJ2aHg0SUZKNUJnQ0xXdF80Q1dCTk9mMUVkNXJuR0oyb014MkFGbFVEa0…
SXTC Stock Rockets On Massive Reverse Split Volatility - StocksToTrade
<a href="https://news.google.com/rss/articles/CBMijAFBVV95cUxNWVhDSHZZeHloR3dRNlZVdmt6S05VaFRfN2tiTEdCVGpZTkRONkJDX2EyLWx4c2I0YTU5TzUyTkw5MVZuOFdWbWlkVV9OY2dHb1FaNGo5NVN1MVpNLU5XWTZWZ0M5N3M2OFpoLWtSR2RvVEF1bDV1a3hVNDhoQm9ZT3NGMi00b2VpcG4wNg…
SXTC - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE9aa2NJWlN0UzAtYTJYYlJxak1RSWNGNkpxV3JFams2NlVvVm4wbHpJTWZ3UDMwTVQ4TTM2RnZtX2JXWkdhMFE?oc=5" target="_blank">SXTC</a> <font color="#6f6f6f">Finviz</font>…
SXTC — Frequently Asked Questions
What is the current share price of China SXT Pharmaceuticals, Inc. (SXTC)?
As of 2026-09-19 21:16 PDT, China SXT Pharmaceuticals, Inc. (SXTC) trades at $2.24 on NasdaqCM. Its 52-week range is $2.20 to $24,000.00.
What is the market capitalisation of SXTC?
China SXT Pharmaceuticals, Inc. (SXTC) has a market capitalisation of $2.96M on NasdaqCM.
What is the return on equity (ROE) of SXTC?
SXTC has a return on equity (ROE) of -27.49%. Its return on capital employed (ROCE) is -23.43%.
Is SXTC a good stock to buy?
This page provides a data-driven analysis of China SXT Pharmaceuticals, Inc. (SXTC), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.